INVO Fertility (NASDAQ:IVF) Raised to “Hold” at Wall Street Zen

INVO Fertility (NASDAQ:IVF) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

INVO Fertility Stock Performance

Shares of IVF opened at $1.00 on Friday. INVO Fertility has a 12 month low of $0.90 and a 12 month high of $84.40. The firm has a fifty day simple moving average of $1.20 and a 200 day simple moving average of $2.22. The stock has a market capitalization of $2.51 million, a price-to-earnings ratio of -0.03 and a beta of 2.32. The company has a current ratio of 0.71, a quick ratio of 0.67 and a debt-to-equity ratio of 0.03.

INVO Fertility (NASDAQ:IVF) last issued its quarterly earnings results on Friday, August 14th. The company reported $0.35 earnings per share (EPS) for the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%. The firm had revenue of $2.18 million for the quarter.

Hedge Funds Weigh In On INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC bought a new position in shares of INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility at the end of the most recent quarter. Institutional investors own 12.02% of the company’s stock.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.